Compare Essex Property Trust, Inc. (ESS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Eli Lilly And Co — how do they compare? Essex Property Trust, Inc. trades at $297.13 (market cap $18.82B), while Eli Lilly And Co trades at $1,172 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 54.7× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.54%). Which is the better fit depends on your goals.
| ESS | LLY | |
|---|---|---|
Market Cap | $18.82B | $1.03T |
Sector | Real Estate | Health |
52-Week High | $298.33 | $1.24K |
52-Week Low | $239.61 | $625.65 |
Enterprise Value | $25.54B | $1.07T |
Dividend Yield | 3.54% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $297.29, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected soon. Fundamentals show robust profitability with a 30.03% net income margin and $669.67M net income for 2025, though valuation ratios like a P/E of 32.93 appear elevated. Recent news highlights sustainability initiatives and inclusion in the Russell Microcap Index.
The outlook for ESS is cautiously optimistic, supported by high West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts are mixed with a $294.25 consensus price target, slightly below the current price, suggesting limited near-term upside amid solid operational performance.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
